Table 1.

EMICORON increase therapeutic efficacy of FOLFIRI regimen against CRC PDXs

Treatmenta	Regressionb	Stable diseaseb	Progressionb
EMICORON	0/5	1/5	4/5
FOLFIRI	1/5	3/5	1/5
FOLFIRI plus EMICORON	3/5	2/5	0/5

^aTumor fragments derived from passage 1, were coated in Matrigel and implanted s.c. in mice (15–20 mm³/mouse) as described in the legend of fig. 2. When the tumor mass reached about 250 to 300 mm³, treatment started by giving mice FOLFIRI regimen consisting in Irinotecan (CPT-11) i.p. at 15 mg/kg for five consecutive days, followed by 5-Fluorouracil (5-FU) i.p. at 19 mg/kg plus Leucovorin at 20 mg/kg for five consecutive days. EMICORON was administered per os at 15 mg/kg for the next seven days. Five mice were included in each experimental group

^bRegression or stable disease were considered when was observed the reduction or the maintenance, respectively, of the same tumor weight for at least two weeks after the starting of treatment